

**Oxford Biomedica plc**

**Questions and Answers**

---

**ANNUAL GENERAL MEETING**  
**held at the offices of Oxford Biomedica**  
**on 27 May 2021 at 3.00 p.m.**

---

## Oxford Biomedica plc

### ANNUAL GENERAL MEETING

#### Questions and Answers

Any questions answered on the day, sent to us during the meeting or via email in advance of the meeting are outlined below.

*Q Is there a plan to pay a dividend this year?*

A. We are in a place where we see a fantastic opportunity in the world of cell and gene therapy to expand the business. Therefore we are not leveraging profit at this stage and we are growing the business by investing back into the business. It is therefore prudent at this point in time, not to pay a dividend to continue this growth.

*Q Are there any new pipeline drugs being developed in the next 12-18 months?*

A. The lead product that we see going towards the clinic in the nearer term with the right pre-clinical results and the right data, would be OXB-302. This is a CAR-T 5T4 approach to haematological tumours. We expect this to enter the clinic in 18-24 months.

*Q In the Annual Report you state that it's very important for the company to have a US Non-Executive Director. Could you explain the benefits of having a US non- Executive Director?*

A. A lot of our customers are US-based and most of the science around gene and cell therapy is also based in the US. Therefore having insight like we have with Heather, and now with Sam, from the US is very important. The US gene and cell therapy market accounts for more than 60% of the global market today. So our customer base, the market potential, and the types of clients all make it absolutely necessary for the board to get deep insights into these different elements as well as the unique regulatory pathways.

*Q The company now uses 3 suites for the manufacturing of the AstraZeneca COVID-19 vaccine. In the past the company indicated that it considered to use multiple reactors in one suite. Is this a line the company is still pursuing in order to free up suites for other customers?*

- A. What we have proven successful in doing is predicting when we need capacity to move forward and build out the next part and that's what we're thinking about at the moment. Thinking about producing the same drug in two 200L bioreactors in one suite is something we have looked at, it's possible, but it's not something we've pursued as yet but it's something that is always an option to us in the future.